首页
产品目录
分子砌块
按反应类型
烷基化
1-(1-(4-(7-phenyl-5H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
1-(1-(4-(7-phenyl-5H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
1-(1-(4-(7-phenyl-5H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
产品编号 :
ACJOOR380
Cas No. :
612847-09-3
包装规格
纯度
目录价
会员专享价
库存
数量
1mg
95%
¥392
询价
2mg
95%
¥581
询价
5mg
95%
¥975
询价
10mg
95%
¥1578
询价
25mg
95%
¥2767
询价
50mg
95%
¥4139
询价
晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。
基础信息
CAS No.
612847-09-3
英文名称
1-(1-(4-(7-phenyl-5H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
别名
3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one;Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 - CAS 612847-09-3 - Calbiochem;CS-1595;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-on;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-γ],guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-2H-benzimidazol-2-one;2H-BenziMidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-iMidazo[4,5-g]quinoxalin-7-yl)phenyl]Methyl]-4-piperidinyl]-
标准英文名
1-(1-(4-(7-phenyl-5H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
分子式
C3 4 H2 9 N7 O
分子量
551.65
精确分子量
551.24
SMILES
O=C1NC2=C(C=CC=C2)N1C1CCN(CC2=CC=C(C3=C(C4=CC=CC=C4)N=C4C=C5N=CN=C5C=C4N3)C=C2)CC1
标准SMILES
O=C1NC2C=CC=CC=2N1C1CCN(CC2C=CC(=CC=2)C2NC3=CC4=NC=NC4=CC3=NC=2C2C=CC=CC=2)CC1
用途
Akti-1/2 is a highly selective inhibitor of Akt1/Akt2 (IC50 = 58 nM / 210 nM, respectively), with 36-fold greater selectivity for Akt1 over Akt3; it induces apoptosis; inhibits insulin-regulated PEPCK and G6Pase expression and FOXO1 activity in hepatocytes; potently enhances PAR-1-mediated platelet aggregation by blocking PKB; suppresses cell growth in HCC827, NCI-H522, NCI-1651, and PC-9 cells (IC50 = 4.7–9.5 μM); synergistically enhances gefitinib-induced inhibition of cell growth and apoptosis; and inhibits basal and IGF-stimulated phosphorylation of Akt1 and Akt2 in mouse lung tissue in vivo.
InChIKey
IWCQHVUQEFDRIW-UHFFFAOYSA-N